Amylyx Pharmaceuticals (AMLX) EBITDA Margin Growth (3y) (2024)
Amylyx Pharmaceuticals (AMLX) EBITDA Margin Growth (3y) (2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1,129.00 |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 2.00 |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 59.00 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -1,031.00 |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -925.00 |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -46.00 |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6,666.00 |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.40 Bn | 4.40 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -1.01 Mn |